Shares of Bank OZK (NASDAQ:OZK – Get Free Report) traded up 4.3% on Thursday after the company announced better than expected quarterly earnings.The company traded as high as $41.17 and last ...

Bank OZK (OZK) came out with quarterly earnings of $1.47 per share, beating the Zacks Consensus Estimate of $1.42 per share. This compares to earnings of $1.51 per share a year ago. These figures ...

Bank OZK (NASDAQ:OZK – Get Free Report) has earned a consensus recommendation of “Hold” from the nine brokerages that are presently covering the stock, MarketBeat reports.One analyst has ...

Bank OZK has been named the Official Banking Partner RCR, as part of a multi-year sponsorship deal that will see the brand adorn the No. 8 Chevrolet in multiple NASCAR Cup Series events throughout ...

We came across a bullish thesis on Bank OZK (OZK) on Substack by Ryan Hess. In this article, we will summarize the bulls’ thesis on OZK. Bank OZK (OZK)'s share was trading at $49.33 as of Nov 22 nd.

Bank OZK is a well-run business with a large commercial real estate portfolio. Risk from CRE concentration is a concern, but further study shows that this bank shares little in common with ...

Bank OZK may have shifted its growth emphasis away from commercial real estate amid investor worries, but it remains a lending juggernaut at a time when many of its peers are struggling to expand. The ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Bank OZK. Looking at options history for Bank OZK (NASDAQ:OZK) we detected 10 trades. If we consider the specifics of ...

When a Citi analyst downgraded Bank OZK from a buy to a sell, sending the stock price tumbling 17 percent, the news shook the industry. Normally, an analyst’s downgrade is not the center of ...

A Wall Street analyst has lowered his rating on Bank OZK (NASDAQ: OZK) to sell from buy due to concerns about some of the bank's largest loans. Investors are heeding the alarm, sending shares of ...

Bank OZK shares received a double downgrade from buy to sell from Citi. The analyst behind the downgrade is worried about two major projects, as well as the broader life sciences market.